BUZZ - Synopsys shares rise after announcing $1 billion stock buyback agreement
路透社2026/10/05 14:26October 5 - Electronic design automation software company Synopsys (SNPS.N) shares rose 2.4% to $502.62. Synopsys announced a $1 billion accelerated share repurchase agreement with JPMorgan. Under the agreement, the company will initially receive approximately 1.735 million shares. The final number of shares repurchased will depend on the average price of SNPS during the repurchase period. The announcement comes just days after SNPS released its optimistic 2027 performance outlook and recently reached a revenue-sharing agreement with ChatGPT developer OpenAI. The overall strength of the software sector has also supported the stock. Including the current day's gain, the stock is up about 7% so far this year.
October 5 - ** Electronic design automation software company Synopsys (SNPS.N) shares rose 2.4%, closing at $502.62
** Synopsys announced a $1 billion accelerated share repurchase agreement with JPMorgan
** Under the agreement, the company will initially receive approximately 1.735 million shares
** The final number of shares repurchased by the company will depend on the average price of SNPS during the buyback period
** The announcement was made several days after SNPS issued an upbeat 2027 performance outlook (link), and after recently reaching a revenue-sharing agreement with ChatGPT developer OpenAI
** The overall strength of the software sector also provided support for the stock
** Including the daily gain, the stock has risen about 7% so far this year
(To assist non-native English speakers, Reuters provides automated translations of its reports into several other languages. Because automated translation may be inaccurate or lack necessary context, Reuters does not guarantee the accuracy of automated translation texts, which are provided solely for readers' convenience. Reuters accepts no responsibility for any harm or losses arising from the use of automated translation features.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Forex Today: US flash Consumer Sentiment and Canadian jobs in the limelight
Malaysian Ringgit: Fiscal anchor case – MUFG
Nasdaq Drops Over 300 Points After OpenAI's Revenue Comes In $20 Billion Short
BUZZ-Revolution Medicines stock drops due to concerns over pancreatic cancer drug data
On October 8, Revolution Medicines (RVMD.O) shares fell 8.1% in afternoon trading to $185.91. RBC Capital Markets stated that the share price decline appeared to be driven by the latest U.S. Food and Drug Administration (FDA) review documents regarding the company's pancreatic cancer drug Rasonque, particularly the disclosure of objective response rate data for specific RAS mutation subgroups. RBC pointed out that overall survival, rather than objective response rate, is a more meaningful indicator of efficacy, and that the sell-off overlooked Rasonque's broad activity across a variety of RAS mutation subgroups. RBC stated: "While we acknowledge that today's share price decline takes place against the backdrop of overall weakness in the biotech sector, we still believe that the market's reaction to the FDA review documents is an overreaction, given that the drug was approved on the basis of highly clinically meaningful efficacy and has received positive feedback from physicians." Including intraday fluctuations, the stock has more than doubled year-to-date. (Note: For the convenience of non-English speakers, Reuters has automatically translated its reports into several other languages. Automated translations may be inaccurate or lack necessary context; Reuters does not guarantee the accuracy of these automated translations and provides them only for reader convenience. Reuters does not accept liability for any damage or loss arising from the use of automated translation features.)
Crypto prices
More
